PK and Safety of Midostaurin in Subjects With Impaired Hepatic Function and Subjects With Normal Hepatic Function

NCT ID: NCT01429337

Last Updated: 2021-05-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 43 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-03-07
• Study Completion Date: 2020-05-09

Brief Summary

The purpose of this international study was to assess the effect of varying degrees of impaired hepatic function compared to a normal hepatic function (Child-Pugh classification) on the pharmacokinetics and safety of midostaurin.

Detailed Description

Midostaurin was developed for the treatment of patients with hematological and nonhematological malignancies. However, disease complications and various co-medications made it difficult to perform a hepatic impairment study in the targeted patient population.

Metabolism and elimination of midostaurin predominantly occurs in the liver. Patients with impaired hepatic function may have a higher risk to have a decreased elimination or metabolism of midostaurin which may lead to increased systemic exposure or toxicity, hence understanding the impact of an impaired hepatic function on midostaurin PK is important.

Cumulative safety data from over 900 subjects exposed to midostaurin showed that the drug was well tolerated in patients and in healthy subjects, thus, it was appropriate and justifiable to study midostaurin in subjects with varying degrees of hepatic impairment.

Due to the difficulty in enrolling subjects with severe hepatic impairment, an interim analysis was performed when all mild and moderate hepatic impaired subjects, and the respective control subjects, had completed the trial, in order to obtain interim results on the PK and safety of midostaurin in patients with mild and moderate hepatic impairment. The protocol was amended in April 2018 to make the inclusion / exclusion criteria more fitting with enrolling the severe hepatic impairment group. The final study analysis was performed when all severe hepatic impaired subjects, and the matching controls, had completed the study.

Conditions

Hepatic Impairment

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Normal hepatic function - group 1

Matched control for group 2 and 3 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in mild and moderate hepatic function groups. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.

Group Type: EXPERIMENTAL

Midostaurin

Intervention Type: DRUG

Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).

Mild hepatic impairment - group 2

Subjects with mild impaired hepatic function - Child Pugh A classification score 5-6. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.

Group Type: EXPERIMENTAL

Midostaurin

Intervention Type: DRUG

Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).

Moderate hepatic impairment - group 3

Subjects with moderate hepatic function - Child Pugh B classification score 7-9. Subjects will be treated with midostaurin 50mg b.i.d from days 1-6 and 50mg o.d on day 7.

Group Type: EXPERIMENTAL

Midostaurin

Intervention Type: DRUG

Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).

Severe hepatic impairment - group 4

Subjects with severe hepatic impairment function - Child Pugh C classification score 10-15. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.

Group Type: EXPERIMENTAL

Midostaurin

Intervention Type: DRUG

Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.

Normal hepatic function - group 5

Matched control for group 4 - healthy volunteers matched with respect to age, body weight, BMI and gender to subjects in severe hepatic function group. Subjects will be treated with a single dose of midostaurin of 50mg on day 1.

Group Type: EXPERIMENTAL

Midostaurin

Intervention Type: DRUG

Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.

Interventions

Midostaurin

Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour break) from Day 1 to Day 6. On Day 7, midostaurin will be administered in the morning only (between 8-10 AM).

Intervention Type: DRUG

Midostaurin

Midostaurin 25 mg soft gelatin capsules (2 capsules). The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM) on Day 1 only.

Intervention Type: DRUG

Other Intervention Names

PKC412; PKC412

Eligibility Criteria

Inclusion Criteria

• Adult male or female subjects age 18-70 years
• Negative serum beta-hCG pregnancy test for all women prior to starting treatment
• Normal vital signs, body weight, BMI and laboratory test results
• Willing to comply with dietary, fluid and lifestyle restrictions
• Able to communicate well with the Investigator and comply with the requirements of the study.

• Physical signs consistent with hepatic impairment
• CPC score consistent with degree of hepatic impairment
• Serum creatinine <=2xULN
• ANC >1000cells/mm3, hemaglobin >9g/dL, platelet count > 50,000/mm3 (group 2-3 only)

Exclusion Criteria

• Significant neurologic or psychiatric disorder which could compromise participation in the study.
• History of: seizures requiring anti-convulsant therapy; unstable COPD; GI or rectal bleeding 3 weeks prior to study start; Myocardial Infarction within 12 months; unstable or poorly controlled angina or other clinically significant heart disease; clinically significant urinary obstruction or difficulty voiding; clinically significant ECG abnormalities or long QT-interval syndrome; pancreatic injury or pancreatitis
• Concurrent severe / uncontrolled medical conditions
• Significant illness within 2 weeks prior to dosing or hospitalisation within 4 weeks prior to dosing
• Any surgical or medical condition that may significantly affect absorption, distribution, metabolism or excretion of drugs
• Clinically significant ECG abnormalities at screening
• Cotinine levels greater than 500ng/mL (group 1-3) or smokers not willing to limit tobacco or nicotine products equivalent to 10 cigarettes per day (group 4 and 5) for 1 week prior to dosing and throughout hospital confinement
• Consumption of alcohol within 3 days (group 1-3) or within 2 days (groups 4 and 5) prior to dosing or during the study.
• Administration of CYP3A4/5 or P-gp inducing or inhibiting drugs within 14 days prior to dosing or during the study
• Sexually active males unless they use condom during intercourse while taking midostaurin and for at least 3 months after the last exposure to drug.
• Use of any prescription drug within 2 weeks or over the counter medication within 72 hours prior to dosing
• Consumption of grapefruit, grapefruit juice, Seville oranges, start fruit / juice within 72 hours prior to dosing

• Clinical evidence of liver disease or liver injury
• Positive HBsAg or Hep C test result

• Symptoms or history of >=G3 hepatic encephalopathy; surgical portosystemic shunt
• PTT >2.5xULN; INR >3; Total bilirubin >6mg/dL
• Evidence of progressive liver disease within 4 weeks prior to starting study
• Clinical evidence of severe >=G3 ascites (groups 2 and 3)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Novartis Pharmaceuticals

Role: STUDY_DIRECTOR

Novartis Pharmaceuticals

Locations

American Research Corporation Inc

San Antonio, Texas, United States

Novartis Investigative Site

Brussels, , Belgium

Novartis Investigative Site

Sofia, , Bulgaria

Novartis Investigative Site

Berlin, , Germany

Novartis Investigative Site

Frankfurt, , Germany

Novartis Investigative Site

Kaunas, LTU, Lithuania

Novartis Investigative Site

Cluj-Napoca, Napoca, Romania

Countries

United States; Belgium; Bulgaria; Germany; Lithuania; Romania

Related Links

https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=17823

Novartis clinical trials results database

Other Identifiers

2010-020694-16

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

CPKC412A2116

Identifier Type: -

Identifier Source: org_study_id